Skip to main content
REGENERON PHARMACEUTICALS, INC. logo

REGENERON PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · REGN ISIN · US75886F1075 LEI · 549300RCBFWIRX3HYQ56 US Manufacturing
Filings indexed 1,720 across all filing types
Latest filing 2021-11-18 Director's Dealing
Country US United States of America
Listing US REGN

About REGENERON PHARMACEUTICALS, INC.

https://www.regeneron.com/

Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for serious diseases. The company's research and development efforts are focused on a wide range of therapeutic areas, including ophthalmology, cancer, allergic and inflammatory diseases, cardiovascular and metabolic disorders, and rare diseases. Regeneron leverages its expertise in biologics and genetic medicines to translate scientific breakthroughs into transformative treatments for patients.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2021-11-18 English
PRIMARY DOCUMENT
Director's Dealing
2021-11-18 English
PRIMARY DOCUMENT
Director's Dealing
2021-11-17 English
PRIMARY DOCUMENT
Director's Dealing
2021-11-17 English
S-3ASR
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 registration statement filed with the SEC by Regeneron Pharmaceuticals, Inc. It is a shelf registration statement used to register securities for sale to the public, including common stock, preferred stock, debt securities, and warrants. The document includes a prospectus describing the general terms of the securities to be offered and mentions that specific terms will be provided in supplements at the time of offering. This type of filing is related to capital raising activities and financing, not a financial report, earnings release, or other types of filings. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is not merely an announcement or a certification, so it is not RPA or RNS. Confidence is high given the clear identification of the form and its purpose.
2021-11-04 English
10-Q
Interim / Quarterly Report Q3 2021
2021-11-04 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.